Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Equities

Nvidia Slides a Second Straight Day as House China Panel Chair Moolenaar Demands Answers on Chip Sales, Lobbying and Leaked Information

by Team Lumida
November 10, 2026
in Equities
Reading Time: 3 mins read
A A
0
The AI Capex Machine Keeps Roaring — Nvidia’s Manufacturing Partner Hon Hai Crushes Estimates as Server Demand Drowns Out Recession Fears
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • The selling did not stop at one day. Nvidia shares sank a further 4% on Tuesday after closing more than 4% lower on Monday, a roughly 8% two-day slide by our calculation, as investors weighed the fallout from CEO Jensen Huang’s affair with an alleged Chinese spy, CNBC reported.
  • Congress is now pressing three specific questions. Rep. John Moolenaar, R-Mich., who chairs the House Select Committee on China, told CNBC’s “Squawk Box” he wants to know whether Huang shared privileged information with a Chinese spy, whether he was influenced to lobby against curbs on chip sales to China, and whether China got preference for Nvidia’s limited supply of advanced chips.
  • Moolenaar warned against a whitewash. “If it becomes less of an investigation, more of damage control, that’s not going to work because people have to have confidence,” he said, calling the U.S.-China contest “basically a Cold War race with technology.”
  • Rivals are picking up the slack. AMD climbed 5% Tuesday for a third straight gain, after rising 11% Friday and 13% Monday, while Broadcom rose 4%, and Yorkville Ives & Co.’s Dan Ives said Street and investor chatter assigns roughly a 15% chance Huang is removed as CEO.

What Happened?

Nvidia’s two-day decline follows Huang’s email to staff saying he had been “unfaithful” to his wife and had “fallen short” of his responsibilities as CEO. He reportedly had an affair with Alice Huang, an executive at Nvidia customer Megaspeed, whom The New York Times reported U.S. officials had concluded was “a Chinese intelligence asset.” The two Huangs are not related. Moolenaar co-authored a Nov. 5 letter with Rep. Brian Mast, who chairs the House Foreign Affairs Committee, and Rep. Rick Crawford, who chairs the House intelligence panel, asking Huang to appear before their committees, writing that the reports “raise significant national security concerns regarding the PRC’s access to sensitive U.S. technology and information.”

Why It Matters?

The scrutiny is widening beyond Nvidia’s boardroom. Congressional pressure has intensified since lawmakers returned to Washington on Monday, and House Minority Leader Hakeem Jeffries said “we’re going to need a full briefing” on the national security implications. Moolenaar’s questions go to the heart of Nvidia’s China business and its Washington lobbying, which could expose the company to political risk that lasts longer than the internal probe. Ives said a board investigation could take four to six weeks and would weigh on the stock until more news emerges from Nvidia, which helps explain why money is rotating to AMD and Broadcom.

What’s Next?

Investors will watch whether Huang agrees to testify before the three House committees and whether Democrats launch their own oversight push. The outcome of Nvidia’s board investigation, which Ives expects to take four to six weeks, is the key catalyst for the stock. A class-action shareholder suit filed in federal court in San Jose adds a legal track to follow.

Affected Tickers and Coins: NVDA, AMD, AVGO, SMH

Source: CNBC, CNBC

Previous Post

Brent Breaks Below $90 for the First Time Since August as Trump Says the Iran War Could End ‘Fairly Soon,’ Though FGE Sees No Deal

Next Post

Polymarket’s Annualized Revenue Tops $1.8 Billion as US Exchange Volume Jumps to $14.5 Billion, Even as the CFTC Probes the Company

Recommended For You

Wall Street Pay Set to Rise Nearly 4% This Year, With Equities Traders’ Bonuses Up 30% or More as Volatility and IPOs Lift Bank Profits

by Team Lumida
15 minutes ago

Wall Street pay is on track to rise nearly 4% this year, with equities traders’ bonuses seen up 30% or more as volatility and IPOs boosted bank profits.

Read more

Global Macro Funds Have Barely Cut Stock Exposure After the S&P 500’s Worst Week Since 2025, as Goldman Flags Up to $45 Billion of Systematic Selling

by Team Lumida
15 minutes ago

Macro hedge funds kept their stock exposure through last week’s rout, Goldman data show, as systematic signals point to up to $45 billion of S&P selling.

Read more

Rivian CEO Calls 2027 an ‘Inflection Year’ on R2 and Point-to-Point Autonomy, With the Stock Down More Than 80% Since Its IPO

by Team Lumida
20 minutes ago

Five years after its $78 IPO, Rivian’s CEO says the R2 SUV and autonomy make 2027 an ‘inflection year,’ even as Wall Street worries over cash burn.

Read more

Exxon Signs a Preliminary Deal to Explore Drilling in Venezuela, Nearly Two Decades After Its Exit and Months After Its CEO Called the Country ‘Uninvestable’

by Team Lumida
9 hours ago

Exxon signed a memorandum of understanding with Venezuela and PDVSA to evaluate drilling but says any investment needs stable policies and competitive returns.

Read more

Hims & Hers Swings to a Surprise $33 Million Loss as Gross Margin Falls to 57% From 74%, and Guides Q4 Revenue Well Below Estimates

by Team Lumida
9 hours ago

Hims & Hers posted a surprise loss as costs surged, narrowed its full-year sales outlook and guided Q4 revenue below estimates.

Read more

Take-Two’s Revenue Falls to $1.5 Billion and Misses Estimates, but It Raises Its Full-Year Outlook as CEO Zelnick Says ‘GTA VI’ Pre-Orders Are at Unprecedented Levels

by Team Lumida
9 hours ago

Take-Two’s revenue fell short as it narrowed its loss and raised its full-year revenue outlook, with GTA VI pre-orders at record levels ahead of Nov. 19.

Read more

Trump Says Jensen Huang Told Him He Had ‘No Idea’ His Affair Partner Was a Spy, as a Shareholder Class Action Hits Nvidia

by Team Lumida
9 hours ago
Nvidia Defies US Controls: $12 Billion AI Chip Sales in China

Trump said Huang denied knowing his affair partner was a Chinese spy and that the FBI is looking into it, as a class-action suit was filed against Nvidia.

Read more

Skydance Maps Out $6 Billion in Cost Cuts From Merging Paramount and Warner Bros. Discovery, and Warns of a $200 Million Box-Office Hit in Q4

by Team Lumida
9 hours ago
RedBird Puts $4 Billion More Into the $110 Billion Paramount-Warner Deal, Taking Its Stake to $6 Billion

Skydance detailed how it will cut $6 billion over three years, from back-office jobs to streaming, and flagged a $200 million fourth-quarter headwind.

Read more

Trade Desk Jumps as Much as 19% After Crushing Estimates With $736 Million in Revenue and Guiding Q4 to at Least $755 Million, as Sanmina Soars 20%

by Team Lumida
9 hours ago

Trade Desk beat on earnings and revenue and guided Q4 sales far above estimates, leading after-hours movers alongside Sanmina and Plug Power.

Read more

Surgery Partners Rejects a $28-a-Share Bid and Takes HealthSpan’s Sweetened $25 Offer, Valuing the Chain at About $6 Billion

by Team Lumida
1 day ago
Medical AI Has a ‘Proof Problem’: Only 2.4% of FDA-Approved Devices Backed by Trial Data; Nvidia, Microsoft, Google Face Regulatory Headwinds

Surgery Partners rose 12% premarket after HealthSpan raised its bid to $25 a share from $23.50; the board rejected a rival $28 offer as riskier.

Read more
Next Post

Polymarket’s Annualized Revenue Tops $1.8 Billion as US Exchange Volume Jumps to $14.5 Billion, Even as the CFTC Probes the Company

Rivian CEO Calls 2027 an ‘Inflection Year’ on R2 and Point-to-Point Autonomy, With the Stock Down More Than 80% Since Its IPO

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

China’s Economic Struggles: Factory Activity Falls Again

China’s Property Crisis: How Local Governments Are Scrambling for Funds

September 2, 2024
Trump Announces 25% Tariffs on Mexico and Canada, Targeting Border Security and Trade

Trump Orders Halt on Penny Production, Reigniting Cost Debate

February 10, 2025
Amazon Is Adding 20% More Holiday Workers While Online Spending Grows 6.7%

Amazon Is Adding 20% More Holiday Workers While Online Spending Grows 6.7%

October 20, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018